Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended versus single-dose cefazolin prophylaxis in revision hip and knee arthroplasty
NL-OMON22317Not yet recruiting
- Sponsor
- Radboudumc
- Start
- Sep 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cefazolin in periprosthetic joint infection (PJI) and surgical site infection (SSI), sponsored by Radboudumc. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
cefazolin
03
Conditions
periprosthetic joint infection (PJI)surgical site infection (SSI)
Beyond the preview
Go deeper on NL-OMON22317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22317.